Emcure Pharmaceuticals Stock Fundamentals
| EMCURE Stock | 1,373 16.15 1.16% |
Emcure Pharmaceuticals fundamentals help investors to digest information that contributes to Emcure Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Emcure Stock. The fundamental analysis module provides a way to measure Emcure Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emcure Pharmaceuticals stock.
Emcure |
Emcure Pharmaceuticals Company Shares Owned By Insiders Analysis
Emcure Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Emcure Pharmaceuticals Shares Owned By Insiders | 86.77 % |
Most of Emcure Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emcure Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 86% of Emcure Pharmaceuticals are shares owned by insiders. This is much higher than that of the Healthcare sector and notably higher than that of the Drug Manufacturers - Specialty & Generic industry. The shares owned by insiders for all India stocks is notably lower than that of the firm.
Emcure Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Emcure Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Emcure Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emcure Pharmaceuticals competition to find correlations between indicators driving Emcure Pharmaceuticals's intrinsic value. More Info.Emcure Pharmaceuticals is rated below average in profit margin category among its peers. It also is rated below average in operating margin category among its peers reporting about 1.81 of Operating Margin per Profit Margin. Comparative valuation analysis is a catch-all model that can be used if you cannot value Emcure Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Emcure Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Emcure Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emcure Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emcure Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Emcure Pharmaceuticals by comparing valuation metrics of similar companies.Emcure Pharmaceuticals is rated below average in shares owned by insiders category among its peers.
Emcure Fundamentals
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 295.8 B | ||||
| Shares Owned By Insiders | 86.77 % | ||||
| Shares Owned By Institutions | 3.53 % | ||||
| Price To Book | 9.39 X | ||||
| Price To Sales | 3.92 X | ||||
| Revenue | 69.17 B | ||||
| EBITDA | 12.05 B | ||||
| Book Value Per Share | 162.97 X | ||||
| Earnings Per Share | 26.38 X | ||||
| Target Price | 1575.0 | ||||
| Market Capitalization | 270.98 B |
About Emcure Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emcure Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emcure Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emcure Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Emcure Pharmaceuticals is entity of India. It is traded as Stock on NSE exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Emcure Stock
Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.